Pfizer Inc.
PFE | NYSE
$27.74
+$0.08 (+0.29%)
At close: Sep 21, 2026, 4:02 PM ET
$27.75
+$0.01 (+0.04%)
After-hours:
Sep 21, 2026, 7:52 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 62.58B | 63.63B | 59.55B | 100.33B | 81.29B | 41.65B |
Cost of Revenue | 18.57B | 21.78B | 29.21B | 38.24B | 34.41B | 11.77B |
Gross Profit | 44.01B | 41.85B | 30.34B | 62.09B | 46.88B | 29.88B |
Operating Income | 15.44B | 16.48B | 5.29B | 37.55B | 20.79B | 9.09B |
Interest Income | 603M | 545M | 1.62B | 251M | 36M | 73M |
Pretax Income | 7.52B | 8.02B | 1.06B | 34.73B | 24.31B | 7.04B |
Net Income | 7.77B | 8.02B | 2.13B | 31.37B | 22.15B | 9.16B |
Selling & General & Admin | 13.35B | 14.73B | 14.47B | 13.12B | 12.25B | 11.4B |
Research & Development | 11.98B | 10.74B | 10.58B | 11.43B | 13.83B | 9.4B |
Other Expenses | 3.26B | -105M | n/a | n/a | n/a | n/a |
Operating Expenses | 28.58B | 25.36B | 25.05B | 24.54B | 26.08B | 20.8B |
Interest Expense | 2.67B | 3.09B | 2.21B | 1.24B | 1.29B | 1.45B |
Selling & Marketing Expenses | n/a | 3.3B | n/a | n/a | n/a | n/a |
Cost & Expenses | 47.14B | 47.14B | 54.26B | 62.78B | 60.5B | 32.57B |
Income Tax Expense | -266M | -28M | -1.11B | 3.33B | 1.85B | 370M |
Shares Outstanding (Basic) | 5.68B | 5.66B | 5.64B | 5.61B | 5.6B | 5.56B |
Shares Outstanding (Diluted) | 5.69B | 5.7B | 5.71B | 5.73B | 5.71B | 5.63B |
EPS (Basic) | 1.36 | 1.42 | 0.38 | 5.59 | 3.95 | 1.65 |
EPS (Diluted) | 1.36 | 1.41 | 0.37 | 5.47 | 3.88 | 1.63 |
EBITDA | 15.1B | 18.13B | 9.56B | 41.03B | 30.79B | 13.17B |
EBIT | 10.19B | 11.11B | 3.27B | 35.97B | 25.6B | 8.49B |
Depreciation & Amortization | 4.91B | 7.01B | 6.29B | 5.06B | 5.19B | 4.68B |
Add to Watchlist
Select watchlists to add or remove PFE